Consideration of Cannabinoids in the Treatment of Diabetic Peripheral Neuropathic Pain
DOI:
https://doi.org/10.58931/cdet.2023.116Abstract
Diabetic Peripheral Neuropathic Pain (DPNP) is a leading complication of diabetes that can have marked impacts on quality of life, may lead to increased depressive symptoms, and can be difficult to treat due to medication side effects. As a result, there has been growing interest in exploring adjunctive treatment options for chronic neuropathic pain, including medical cannabinoids. While the pathogenesis of DPNP is not fully understood, there is evidence that persistent hyperglycemia contributes to a number of processes leading to vascular damage, increased oxidative stress, and release of free radicals and pro-inflammatory molecules4,5—all of which may lead to DPNP symptoms, including pain.
References
Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab J. 2009 Jun 1;35(3):206-213. doi:10.1016/j.diabet.2008.11.004 DOI: https://doi.org/10.1016/j.diabet.2008.11.004
Alghafri RM, Gatt A, Formosa C. Depression symptoms in patients with diabetic peripheral neuropathy. Rev Diabet Stud. 2020 Jul 30;16(1):35-40. DOI: https://doi.org/10.1900/RDS.2020.16.35
Rosenberg CJ, Watson JC. Treatment of painful diabetic peripheral neuropathy. Prosthet Orthot Int. 2015 Feb;39(1):17-28. doi:10.1177/0309364614542266 DOI: https://doi.org/10.1177/0309364614542266
Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede RD. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm. 2020 Apr;127(4):589-624. doi:10.1007/s00702-020-02145-7 DOI: https://doi.org/10.1007/s00702-020-02145-7
Etienne I, Magalhães LV, Cardoso SA, de Freitas RB, de Oliveira GP, Palotás A, et al. Oxidative stress markers in cognitively intact patients with diabetic neuropathy. Brain Res Bull. 2019 Aug 1;150:196-200. DOI: https://doi.org/10.1016/j.brainresbull.2019.06.001
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018 Mar 13;19(3):833. DOI: https://doi.org/10.3390/ijms19030833
Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2019 Dec 25;9(1):21. doi:10.3390/antiox9010021 DOI: https://doi.org/10.3390/antiox9010021
Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and cannabinoid research. 2017 Jun 1;2(1):139-154. DOI: https://doi.org/10.1089/can.2016.0034
Moulin DE, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research and Management. 2014 Nov 1;19(6):328-335. DOI: https://doi.org/10.1155/2014/754693
Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018 Oct;22(9):1547-1564. DOI: https://doi.org/10.1002/ejp.1297
Petzke F, Karst M, Gastmeier K, Radbruch L, Steffen E, Häuser W. Ein Positionspapier zu medizinischem Cannabis und cannabisbasierten Medikamenten in der Schmerzmedizin. Der Schmerz. 2019 Oct;33(5):449-465. DOI: https://doi.org/10.1007/s00482-019-00407-2
Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176:325–352. doi:10.1016/j.neurol.2020.01.361 DOI: https://doi.org/10.1016/j.neurol.2020.01.361
Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS, et al. J. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: Report of the AAN Guideline Subcommittee. Neurology. 2022 Jan 4;98(1):31-43. doi:10.1212/wnl.0000000000013038 DOI: https://doi.org/10.1212/WNL.0000000000013038
Weizman L, Dayan L, Brill S, et al. Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity. Neurology. 2018;91(14):e1285-e1294. DOI: https://doi.org/10.1212/WNL.0000000000006293
Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390-402. DOI: https://doi.org/10.2174/1389201020666191202111534
Ueberall MA, Essner U, Mueller-Schwefe GH. Effectiveness and tolerability of THC: CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res. 2019;12:1577. DOI: https://doi.org/10.2147/JPR.S192174
Ueberall MA, Essner U, Silván CV, Mueller-Schwefe GH. Comparison of the effectiveness and tolerability of nabiximols (THC: CBD) oromucosal spray versus oral dronabinol (THC) as add-on treatment for severe neuropathic pain in real-world clinical practice: retrospective analysis of the German pain e-registry. J Pain Res. 2022;15:267. DOI: https://doi.org/10.2147/JPR.S340968
Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021 Dec;3(1):1-2. doi:0.1186/s42238-021-00073-1 DOI: https://doi.org/10.1186/s42238-021-00073-1
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Diabetes & Endocrinology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
